Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders Review uri icon

Overview

MeSH Major

  • Janus Kinase 2
  • Myeloproliferative Disorders

abstract

  • The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors. The genetic cause of these diseases was not known until 2005, when several independent groups demonstrated that most patients with PV, ET and PMF acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). These discoveries have changed the landscape for diagnosis and classification of PV, ET and PMF, and show the ability of genomic technologies to identify new molecular targets in human malignancies with pathogenetic, diagnostic and therapeutic significance.

publication date

  • September 2007

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/nrc2210

PubMed ID

  • 17721432

Additional Document Info

start page

  • 673

end page

  • 83

volume

  • 7

number

  • 9